FibroBiologics, Inc. (FBLG)
1.36
-0.07
(-4.90%)
USD |
NASDAQ |
Sep 21, 16:00
1.48
+0.12
(+8.82%)
After-Hours: 04:50
FibroBiologics Enterprise Value : 6.217M for Sept. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 21, 2026 | 6.217M |
| September 18, 2026 | 6.642M |
| September 17, 2026 | 6.977M |
| September 16, 2026 | 6.642M |
| September 15, 2026 | 6.703M |
| September 14, 2026 | 7.372M |
| September 11, 2026 | 7.737M |
| September 10, 2026 | 8.466M |
| September 09, 2026 | 8.649M |
| September 08, 2026 | 8.345M |
| September 04, 2026 | 8.953M |
| September 03, 2026 | 8.649M |
| September 02, 2026 | 9.804M |
| September 01, 2026 | 10.78M |
| August 31, 2026 | 8.406M |
| August 28, 2026 | 6.703M |
| August 27, 2026 | 7.007M |
| August 26, 2026 | 6.521M |
| August 25, 2026 | 6.460M |
| August 24, 2026 | 6.156M |
| August 21, 2026 | 6.703M |
| August 20, 2026 | 5.791M |
| August 19, 2026 | 5.183M |
| August 18, 2026 | 4.879M |
| August 17, 2026 | 4.149M |
| Date | Value |
|---|---|
| August 14, 2026 | 4.392M |
| August 13, 2026 | 4.940M |
| August 12, 2026 | 4.696M |
| August 11, 2026 | 4.21M |
| August 10, 2026 | 3.906M |
| August 07, 2026 | 3.883M |
| August 06, 2026 | 4.149M |
| August 05, 2026 | 3.225M |
| August 04, 2026 | 2.945M |
| August 03, 2026 | 2.754M |
| July 31, 2026 | 2.203M |
| July 30, 2026 | 2.320M |
| July 29, 2026 | 1.927M |
| July 28, 2026 | 1.902M |
| July 27, 2026 | 1.760M |
| July 24, 2026 | 2.276M |
| July 23, 2026 | 2.419M |
| July 22, 2026 | 2.447M |
| July 21, 2026 | 2.648M |
| July 20, 2026 | 2.696M |
| July 17, 2026 | 3.024M |
| July 16, 2026 | 3.054M |
| July 15, 2026 | 3.072M |
| July 14, 2026 | 3.125M |
| July 13, 2026 | 3.168M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.661B |
| Alnylam Pharmaceuticals, Inc. | 32.35B |
| Anika Therapeutics, Inc. | 263.87M |
| Savara, Inc. | 976.80M |
| Vericel Corp. | 1.956B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.117M |
| Total Expenses (Quarterly) | 4.117M |
| EPS Diluted (Quarterly) | -0.6564 |
| Earnings Yield | -414.7% |
| Normalized Earnings Yield | -388.56 |